JNJ 440

Drug Profile

JNJ 440

Alternative Names: ALS-003440; JNJ-64530440

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alios BioPharma
  • Class Antivirals; Hepatoprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 26 Mar 2018 Phase-I clinical trials in Hepatitis B in New Zealand (PO) (NCT03439488)
  • 22 Feb 2018 Alios Biopharma plans a first in human phase I trial for Hepatitis B (In volunteers) in New Zealand (PO) in February 2018 (NCT03439488) (EudraCT2017-004657-17)
  • 05 Dec 2017 Preclinical trials in Hepatitis B in New Zealand (PO) before December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top